Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.91 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.64 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.63 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | ACACB | O00763 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21444578 | 1.00 | RECQL (0.91) | RECQLPOLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL517633 | 1.00 | RECQL (0.91) | RECQLPOLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL9057935 | 0.98 | RECQL (0.94) | RECQLPOLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20663584 | 0.95 | RECQL (1.00) | RECQLPOLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15038847 | 0.95 | RECQL (1.00) | RECQLPOLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15038846 | 0.92 | RECQL (0.87) | RECQLPOLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL19884283 | 0.92 | RECQL (0.87) | RECQLPOLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14314483 | 0.92 | RECQL (0.87) | RECQLPOLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5521105 | 0.86 | POLB (0.73) | RECQLPOLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1909826 | 0.86 | RECQL (0.77) | RECQLPOLBLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103339111-A | Bicyclic acetyl-CoA carboxylase inhibitors | NOVARTIS AG | 2013-10-02 | — | — | CN | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011022638-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| US-7361666-B2 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR, INC. (US) | 2008-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | RECQL 3766/4885POLB 4356/4885LMNA 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.